Novavax (NVAX) Current Deferred Revenue (2010 - 2026)

Novavax's Current Deferred Revenue history runs 17 years deep, the most recent figure standing at $88.8 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 82.86% year-over-year to $88.8 million in Q1 2026; TTM through Mar 2026 was $88.8 million, a 82.86% decrease from a year earlier, with the FY2025 full-year figure at $499.0 million, down 55.52% from the prior year.
• Current Deferred Revenue declined to $88.8 million in Q1 2026 per NVAX's latest filing, from $499.0 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $1.5 billion in Q1 2022 and bottomed at $88.8 million in Q1 2026.
• The 5-year median for Current Deferred Revenue is $863.5 million (2023), against an average of $879.0 million.
• Across the five-year window, Current Deferred Revenue surged 86.68% in 2022 and tumbled 82.86% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $549.6 million in 2022, then surged by 57.13% to $863.5 million in 2023, then grew by 29.92% to $1.1 billion in 2024, then sank by 55.52% to $499.0 million in 2025, then tumbled by 82.21% to $88.8 million in 2026.
• Per Business Quant, the three latest NVAX Current Deferred Revenue figures stand at $88.8 million (Q1 2026), $499.0 million (Q4 2025), and $500.0 million (Q3 2025).